Farmingdale, NY, Oct. 10, 2017 -- Cemtrex Inc., (Nasdaq: CETX, CETXP, CETXW), a world-leading industrial and manufacturing company, today announced that the company was recently selected by Crain’s New York Business as one of its “ 50 fastest-growing companies in the New York area ” for 2017. The list honors 50 of the most innovative firms for their winning strategies and significant revenue growth. The magazine notes that it arrives at its annual list by analyzing the financial statements of candidates with at least $10 million in revenue and ranking them by their three-year growth rate, assisted by the accounting firm Anchin, Block and Anchin.
Cemtrex ranked #33 on this list, with Crains citing that, “The public company's strategy has been to seek customers in emerging economies worldwide and pockets of industry in the U.S. that are expanding rapidly, such as the manufacturing of medical devices and automotive electronics.” Cemtrex achieved revenue growth of 585% from 2013 to 2016 as the Company’s sales increased from $13.7 million to 93.7 million.
Cemtrex’s CEO, Saagar Govil, commented, “We are honored to be recognized by Crain’s New York Business. Cemtrex has been one of the fastest growing industrial companies over the last several years in terms of revenue and our goal is to maintain that trend through organic growth and an accretive M&A strategy. We are proud to help companies like Johnson Controls, ABB, and Schneider Electric be more efficient and make great products every day.”
To read Crain’s New York Business findings, please click here.
About Cemtrex
Cemtrex, Inc. (NASDAQ:CETX) is an international diversified industrial and manufacturing company that provides a wide array of solutions to meet today’s technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics design and manufacturing services, comprehensive industrial services, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants. The Company is also in the process of developing its own proprietary IoT and wearable devices. For more information about Cemtrex, please visit www.cemtrex.com.
Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.
Investor Relations Cemtrex, Inc. Phone: 631-756-9116 [email protected]


Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



